

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	· FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/071,541	05/04/1998	HJ. SU HUANG	040750-5001	- 5607	
9629	7590 07/03/2003				
MORGAN LEWIS & BOCKIUS LLP			EXAMINER		
• • • • • • • • • • • • • • • • • • • •	YLVANIA AVENUE NW ON, DC 20004 _.		FONDA, KATHI	FONDA, KATHLEEN KAHLER	
			ART UNIT	PAPER NUMBER	
			1623	21	
			DATE MAILED: 07/03/2003	. //	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	pplicant(s)	
Advisory Action	09/071,541	HUANG ET AL.	
Advisory Action	Examin r	Art Unit	
	Kathleen Kahler Fonda, Ph.D.	1623	
The MAILING DATE of this communicati n appe	ars n the cover sheet with the c	orrespondence address	
THE REPLY FILED 28 April 2003 FAILS TO PLACE THI Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment whicl	ation. A proper reply to a places the application in	d
PERIOD FOR RE	PLY [check either a) or b)]		
a) The period for reply expiresmonths from the mailing	- ·		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment.	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount of the shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPE R 1.136(a) and the appropriate ext unt of the fee. The appropriate ext originally set in the final Office acti	P ension tension on; or
1. A Notice of Appeal was filed on <u>28 April 2003</u> . Appe 37 CFR 1.192(a), or any extension thereof (37 CFF			
2. The proposed amendment(s) will not be entered be	ecause:		
(a) they raise new issues that would require further	er consideration and/or search (see NOTE below);	
(b) they raise the issue of new matter (see Note b	elow);		
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying	the
(d) they present additional claims without cancell NOTE:	ng a corresponding number of f	nally rejected claims.	
3.⊠ Applicant's reply has overcome the following reject	ion(s): all under sections 112 ar	nd 102.	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendm	ent
5. ☑ The a) ☑ affidavit, b) ☐ exhibit, or c) ☑ request for application in condition for allowance because: See		dered but does NOT place t	he
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: <u>none</u> .			
Claim(s) objected to: none.			
Claim(s) rejected: 1-16.			
Claim(s) withdrawn from consideration: none.			
8. \square The proposed drawing correction filed on is	a)□ approved or b)□ disapp	roved by the Examiner.	
9. Note the attached Information Disclosure Statemer	nt(s)(PTO-1449) Paper No(s)		
10. Other:		_	
		Kathleen Kahler Fonda, Ph.I Primary Examiner Art Unit: 1623	- O.

U.S. Patent and Trademark Office PTO-303 (Rev. 04-01) Continuation of 5. does NOT place the application in condition for allowance because: the claims are obvious under 103 for reasons of record. The references as applied suggest combining a tyrosine kinase inhibitor with an apoptosis inducer as claimed, to enhance the sensitivity of cancer cells to the apoptosis inducer.